[ad_1]
The president of the United States, Donald Trump, also received it: Remdesivir. It was the first drug approved for the treatment of Covid-19, but a new WHO study casts doubt on its efficacy.
According to the World Health Organization (WHO), several potential corona drugs tested in series of tests around the world have shown little or no benefit. This stems from data from the WHO-coordinated solidarity study, which has yet to appear in a peer-reviewed journal.
Remdesivir, who was infected with the virus by US President Donald Trump, was one of the agents reviewed. SARS-CoV-2 received. The drug is also approved in Europe for the treatment of Covid-19.
The manufacturer emphasizes the effectiveness of its drug.
Remdesivir’s maker, Gilead, reiterated its drug’s effectiveness on Friday. It is concerned that the data in the WHO study have not undergone the usual rigorous scrutiny.
Interim results suggested that the tested drugs had little to no effect, the WHO said on Friday. Among other things, they examined the effect they had on mortality, the timing of ventilators used, and the length of hospital stay.
Study with thousands of patients in more than 30 countries
As part of the WHO-coordinated solidarity study with thousands of patients in nearly 500 clinics in more than 30 countries, remdesivir, chloroquine / hydroxychloroquine, lopinavir / ritonavir, and the interferon regimen were tested. The drugs were originally developed for other diseases.
The WHO also emphasized that the results have not yet been published, but have not yet been peer-reviewed. A manuscript was uploaded to the Yale University medRxiv server.
Important note: In no case is the information a substitute for professional advice or treatment by trained and recognized doctors. The content of t-online.de cannot and should not be used for independent diagnosis or initiation of treatment.
